NASDAQ:XBIOW Xenetic Biosciences (XBIOW) Stock Price, News & Analysis → Special FREE offer on stock hotsheets (From DTI) (Ad) Free XBIOW Stock Alerts $7.75 +0.55 (+7.64%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$7.75▼$7.7550-Day Range$7.20▼$14.8052-Week Range$0.81▼$23.16Volume660 shsAverage Volume718 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Xenetic Biosciences alerts: Email Address Ad DTIStuck in your old ways? If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses…You can find out about this “2-Click Trade” here. About Xenetic Biosciences Stock (NASDAQ:XBIOW)Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Read More XBIOW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIOW Stock News HeadlinesMarch 22, 2024 | msn.comXBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023March 22, 2024 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsMay 7, 2024 | DTI (Ad)Special FREE offer on stock hotsheetsThese sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?January 17, 2024 | finance.yahoo.comXenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformNovember 10, 2023 | msn.comXenetic Biosciences reports Q3 resultsNovember 10, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports Third Quarter 2023 Financial ResultsSeptember 27, 2023 | investing.comXENX Historical DataSeptember 1, 2023 | finance.yahoo.comXenetic Biosciences, Inc. (XBIOW)May 7, 2024 | TradeSmith (Ad)30-day gains?Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.August 11, 2023 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue EstimatesJuly 12, 2023 | marketwatch.comXenetic Biosciences Shares Down 15% After Presentation, Tuesday IncreaseJuly 5, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight SeriesJune 12, 2023 | ca.finance.yahoo.comXBIOW - Xenetic Biosciences, Inc.See More Headlines Receive XBIOW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:XBIOW CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone17817787720FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.54 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg Esq. (Age 58)CEO, President & Director Comp: $533.95kMr. James F. Parslow (Age 59)CFO, COO & Corporate Secretary Comp: $424.55kDr. Curtis A. Lockshin (Age 64)Chief Scientific Officer Comp: $420.93kKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors XBIOW Stock Analysis - Frequently Asked Questions How have XBIOW shares performed in 2024? Xenetic Biosciences' stock was trading at $4.00 at the start of the year. Since then, XBIOW stock has increased by 93.8% and is now trading at $7.75. View the best growth stocks for 2024 here. Are investors shorting Xenetic Biosciences? Xenetic Biosciences saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 200 shares, a decline of 50.0% from the March 31st total of 400 shares. Based on an average trading volume of 300 shares, the days-to-cover ratio is currently 0.7 days. View Xenetic Biosciences' Short Interest. How do I buy shares of Xenetic Biosciences? Shares of XBIOW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIOW) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaBiden replacement revealed?Paradigm PressThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
